Cytokinetics, Incorporated

NasdaqGS:CYTK Stock Report

Market Cap: US$8.2b

Cytokinetics Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

NasdaqGS:CYTK Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
01 Apr 26SellUS$499,725Robert BlumIndividual7,500US$66.63
18 Mar 26SellUS$650,680Andrew CallosIndividual10,472US$62.15
17 Mar 26SellUS$2,274,752Robert BlumIndividual36,601US$62.15
17 Mar 26SellUS$306,710Sung LeeIndividual4,935US$62.15
17 Mar 26SellUS$747,851Fady MalikIndividual12,033US$62.15
16 Mar 26SellUS$104,300Andrew CallosIndividual1,709US$61.03
09 Mar 26SellUS$176,513Fady MalikIndividual2,907US$60.72
09 Mar 26SellUS$156,779Andrew CallosIndividual2,582US$60.72
09 Mar 26SellUS$481,570Robert BlumIndividual7,931US$60.72
02 Mar 26SellUS$306,050B. ParshallIndividual5,000US$61.21
02 Jan 26SellUS$56,688Andrew CallosIndividual913US$62.09
29 Dec 25SellUS$112,954Andrew CallosIndividual1,809US$62.44
01 Dec 25SellUS$143,620Robert HarringtonIndividual2,150US$66.80
19 Nov 25SellUS$323,650B. ParshallIndividual5,000US$64.73
30 Oct 25SellUS$314,300Robert BlumIndividual5,000US$62.86
06 Oct 25SellUS$405,420Edward KayeIndividual6,757US$60.00
01 Oct 25SellUS$275,250Robert BlumIndividual5,000US$55.05
30 Sep 25SellUS$368,761Edward KayeIndividual6,695US$55.08
15 Sep 25SellUS$248,850Robert BlumIndividual5,000US$49.77
02 Sep 25SellUS$243,800Robert BlumIndividual5,000US$48.76
02 Sep 25SellUS$104,641Robert HarringtonIndividual2,150US$48.67
02 Sep 25SellUS$337,800Edward KayeIndividual6,756US$50.00
15 Aug 25SellUS$192,100Robert BlumIndividual5,000US$38.42
29 Jul 25SellUS$182,250Robert BlumIndividual5,000US$36.45
14 Jul 25SellUS$190,750Robert BlumIndividual5,000US$38.15
01 Jul 25SellUS$167,750Robert BlumIndividual5,000US$33.55
16 Jun 25SellUS$169,000Robert BlumIndividual5,000US$33.80
05 Jun 25SellUS$277,434Andrew CallosIndividual8,659US$32.04
05 Jun 25SellUS$116,716Edward KayeIndividual3,636US$32.10
02 Jun 25SellUS$156,100Robert BlumIndividual5,000US$31.22
16 May 25SellUS$154,650Robert BlumIndividual5,000US$30.93
15 May 25SellUS$43,227Muna BhanjiIndividual1,454US$29.73
05 May 25SellUS$146,793Andrew CallosIndividual4,002US$36.68
29 Apr 25SellUS$204,800Robert BlumIndividual5,000US$40.96

Insider Trading Volume

Insider Buying: CYTK insiders have only sold shares in the past 3 months.

Ownership Breakdown

What is the ownership structure of CYTK?
Owner TypeNumber of SharesOwnership Percentage
State or Government37,5060.0266%
Individual Insiders829,7100.588%
Institutions140,143,42699.4%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Top 25 shareholders own 86.37% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
16%
T. Rowe Price Group, Inc.
19,646,491US$1.3b-8.47%0.11%
13.3%
BlackRock, Inc.
16,394,780US$1.1b5.6%0.01%
10.4%
FMR LLC
12,799,216US$853.6m-2.18%0.04%
9.78%
The Vanguard Group, Inc.
12,048,131US$803.5m1.61%0.01%
6.44%
Wellington Management Group LLP
7,937,063US$529.3m7.13%0.08%
4.73%
State Street Global Advisors, Inc.
5,825,295US$388.5m3.7%0.01%
2.71%
Deep Track Capital, LP
3,336,998US$222.5m-22.4%4.33%
2.48%
Geode Capital Management, LLC
3,056,017US$203.8m0.52%0.01%
2.32%
Bank of America Corporation
2,853,516US$190.3m-4.54%0.04%
2.21%
RTW Investments, LP
2,721,158US$181.5m0%1.86%
1.97%
Polar Capital Holdings Plc
2,422,612US$161.6m-13%0.4%
1.38%
The Goldman Sachs Group, Inc.
1,696,004US$113.1m48.1%0.04%
1.34%
Woodline Partners LP
1,648,428US$109.9m0.04%0.42%
1.14%
Integral Health Asset Management, LLC
1,400,000US$93.4m0%4.83%
1.12%
Charles Schwab Investment Management, Inc.
1,383,437US$92.3m0%0.01%
1.12%
Northern Trust Global Investments
1,380,787US$92.1m-1.85%0.01%
1.11%
UBS Asset Management AG
1,366,505US$91.1m-33.1%0.01%
0.96%
Capital Research and Management Company
1,178,780US$78.6m0%no data
0.94%
Citadel Advisors LLC
1,162,937US$77.6m-16.1%0.05%
0.92%
JP Morgan Asset Management
1,130,550US$75.4m22.2%0.01%
0.84%
Susquehanna International Group, LLP
1,032,046US$68.8m-20.4%0.08%
0.81%
Morgan Stanley
1,003,175US$66.9m-21.2%0.01%
0.81%
Armistice Capital LLC
992,766US$66.2m-17.1%1.59%
0.8%
RP Management, LLC
980,392US$65.4m0%29.25%
0.79%
Principal Global Investors, LLC
976,892US$65.1m-16.8%0.03%

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/04/14 01:23
End of Day Share Price 2026/04/13 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Cytokinetics, Incorporated is covered by 36 analysts. 19 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Emily FieldBarclays
Hang HuBarclays
Carter GouldBarclays